

PRODUCT DATASHEET

ChemiScreen™ BB3 Bombesin Membrane Preparation

CATALOG NUMBER: HTS160M QUANTITY: 200 units

LOT NUMBER: 2037899 VOLUME/CONCENTRATION: 2 mL, 1 mg/mL

BACKGROUND: Bombesin, a bioactive peptide first identified in amphibian skin, is related to two mammalian

peptides, *gastrin*-releasing peptide (GRP) and neuromedin B (NMB). A family of 3 GPCRs, including NMB-R (BB₁), GRP-R (BB₂) and BRS-3 (BB₃), mediate the biological effects of the peptides. The receptors differ in their affinities for the peptides; BB₂ binds to GRP with 50-300-fold greater affinity than to NMB, whereas BB₁ binds to NMB with 10-800-fold greater affinity than to GRP (Tokita *et al.*, 2004). Binding of ligand to BB₁ activates G_q to increase intracellular calcium concentrations. The CNS is a major site of NMB and BB₁ expression, and BB₁ appears to be involved in thermoregulation (Ohki-Hamazaki *et al.*, 2005). BB1 membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of antagonists of BB1 interactions with neuromedin B.

APPLICATIONS: Radioligand binding assay





Figure 1. Saturation binding for BB₃. 5 μ g/well BB₃ Membrane Preparation was incubated with increasing amount of ¹²⁵I-labeled Bombesin (6-14) Analog in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 500-fold excess unlabeled Bombesin (6-14) Analog. Specific binding (SB) was determined by subtracting NSB from TB. Sample data from a representative lot.



Discovery Services



[Unlabel Bombesin (6-14) Analog] Log M

Figure 2. Competition binding for BB3. BB $_3$ Membrane Preparation and WT-Chem-1 Membrane Preparation (Millipore HTS000MC1), each at 10 μg/well in a 96-well plate, was incubated with 0.3 nM 125 I-labeled Bombesin (6-14) Analog and increasing concentrations of unlabeled Bombesin (6-14) Analog. The reaction was then subjected to filtration binding, and greater than 5-fold signal:background was obtained. Representative sample data

SPECIFICATIONS: 1 unit = 10 μg membrane preparation

B_{max} 0.95 pmol/mg

K_d 0.3 nM

Species: Full length human BRS3 encoding BB3 (Accession number NM_001727)

HOST CELLS: Chem-1, an adherent mammalian cell line without any endogenous BB3

expression.

RECOMMENDED ASSAY CONDITIONS: Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, an FC 96-well harvest plate (Millipore cat. # MAHF C1H) is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl₂, 1 mM CaCl₂, 0.2% BSA, 0.2 mg/ml

bacitracin, 20 μg/ml leupeptin, 20 μg/ml chymostatin, 1 Protease Inhibitor cocktail Tablets (Roche Cat. No. 11 873 580 001) for each 50 ml binding

buffer.

Radioligand: [125]-Bombesin (6-14) Analog (Perkin Elmer NEX377)

Wash Buffer: 50 mM Hepes, pH 7.4, 500 mM NaCl, 0.1% BSA, filtered and stored at

4°C.

One package contains enough membranes for at least 200 assays (units), where an unit is the amount of membrane that will yield greater than 5-fold signal:background with ¹²⁵l-labeled Bombesin (6-14) Analog at 0.3 nM.

PRESENTATION:

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no preservatives.

Packaging method: Membrane proteins were adjusted to the indicated concentration in



Discovery Services

packaging buffer, rapidly frozen, and stored at -80°C.

STORAGE/HANDLING:

Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored

as directed. Do not freeze and thaw.

REFERENCES:

- Matsumoto K and Iijima H (2003) Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice. *Eur. J. Pharmacol.* 473: 41-46.
- 2. Ohki-Hamazaki H et al. (2005) Development and function of bombesin-like peptides and their receptors. *Int. J. Dev. Biol.* 49: 293-300.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services